Status:
RECRUITING
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
Lead Sponsor:
The Second Hospital of Anhui Medical University
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia/reperfusion injury in AMI patients. It will also asses...
Detailed Description
Acute ST-segment elevation myocardial infarction (STEMI) patients (aged ≥18 years) planned for percutaneous coronary intervention (PCI) will be enrolled for this study. Patients with severe complicati...
Eligibility Criteria
Inclusion
- Aged ≥18 years, Male or Female.
- Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW).
- Within 24 hours of the onset of infarct-related chest pain.
- Obtaining informed consent from the patient and their family.
Exclusion
- Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall;
- Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs;
- Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection;
- Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies;
- Pregnant or breastfeeding women;
- Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure;
- Patients with severe infections;
- Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs;
- Other patients considered unsuitable for this study by the researchers.
Key Trial Info
Start Date :
May 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT06947135
Start Date
May 29 2025
End Date
June 30 2026
Last Update
December 17 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230022
2
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230032
3
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410011